{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:50:31Z","timestamp":1791942631736,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Anticancer Association EYAS PROJECT","award":["SACA-CY22B02, ZYJH202309"],"award-info":[{"award-number":["SACA-CY22B02, ZYJH202309"]}]},{"name":"Shanghai Anticancer Association EYAS PROJECT","award":["SACA-CY22B02, ZYJH202309"],"award-info":[{"award-number":["SACA-CY22B02, ZYJH202309"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82002670, 82103408, 82272930, 82372793, 82373276"],"award-info":[{"award-number":["82002670, 82103408, 82272930, 82372793, 82373276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"crossref","award":["22ZR1413400, 23ZR1411700, 23ZR1440300"],"award-info":[{"award-number":["22ZR1413400, 23ZR1411700, 23ZR1440300"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Sailing Program","award":["21YF1407000"],"award-info":[{"award-number":["21YF1407000"]}]},{"name":"Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation","award":["YJYQ201802"],"award-info":[{"award-number":["YJYQ201802"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["BX20230091"],"award-info":[{"award-number":["BX20230091"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Luminal and Basal are the primary intrinsic subtypes of muscle-invasive bladder cancer (MIBC). The presence of CD8<jats:sup>+<\/jats:sup> T cells infiltration holds significant immunological relevance, potentially influencing the efficacy of antitumor responses. This study aims to synergize the influence of molecular subtypes and CD8<jats:sup>+<\/jats:sup> T cells infiltration in MIBC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 889 patients with MIBC from Zhongshan Hospital, The Cancer Genome Atlas, IMvigor210 and NCT03179943 cohorts. We classified the patients into four distinct groups, based on the interplay of molecular subtypes and CD8<jats:sup>+<\/jats:sup> T cells and probed into the clinical implications of these subgroups in MIBC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among patients with Luminal-CD8<jats:sup>+<\/jats:sup>T<jats:sup>high<\/jats:sup> tumors, the confluence of elevated tumor mutational burden and PD-L1 expression correlated with a heightened potential for positive responses to immunotherapy. In contrast, patients featured by Luminal-CD8<jats:sup>+<\/jats:sup>T<jats:sup>low<\/jats:sup> displayed a proclivity for deriving clinical advantages from innovative targeted interventions. The Basal-CD8<jats:sup>+<\/jats:sup>T<jats:sup>low<\/jats:sup> subgroup exhibited the least favorable three-year overall survival outcome, whereas their Basal-CD8<jats:sup>+<\/jats:sup>T<jats:sup>high<\/jats:sup> counterparts exhibited a heightened responsiveness to chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We emphasized the significant role of immune-molecular subtypes in shaping therapeutic approaches for MIBC. This insight establishes a foundation to refine the process of selecting subtype-specific treatments, thereby advancing personalized interventions for patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-024-03651-3","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T13:01:28Z","timestamp":1709384488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Bingyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaopei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"3651_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3651_CR2","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y (2017) Bladder cancer. Nat Rev Dis Primers 3:17022. https:\/\/doi.org\/10.1038\/nrdp.2017.22","journal-title":"Nat Rev Dis Primers"},{"key":"3651_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","volume":"81","author":"R Cathomas","year":"2022","unstructured":"Cathomas R, Lorch A, Bruins HM et al (2022) The 2021 updated european association of urology guidelines on metastatic urothelial carcinoma. Eur Urol 81:95\u2013103. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.026","journal-title":"Eur Urol"},{"key":"3651_CR4","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/s0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 387:1909\u20131920. https:\/\/doi.org\/10.1016\/s0140-6736(16)00561-4","journal-title":"Lancet (London, England)"},{"key":"3651_CR5","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, Hoadley KA, Chism DD et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111:3110\u20133115. https:\/\/doi.org\/10.1073\/pnas.1318376111","journal-title":"Proc Natl Acad Sci USA"},{"key":"3651_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152\u2013165. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.009","journal-title":"Cancer Cell"},{"key":"3651_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315\u2013322. https:\/\/doi.org\/10.1038\/nature12965","journal-title":"Nature"},{"key":"3651_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England) 389:67\u201376. https:\/\/doi.org\/10.1016\/s0140-6736(16)32455-2","journal-title":"Lancet (London, England)"},{"key":"3651_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203\u2013213. https:\/\/doi.org\/10.1056\/NEJMoa020177","journal-title":"N Engl J Med"},{"key":"3651_CR10","first-page":"1555","volume":"63","author":"Y Cho","year":"2003","unstructured":"Cho Y, Miyamoto M, Kato K et al (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Can Res 63:1555\u20131559","journal-title":"Can Res"},{"key":"3651_CR11","first-page":"3491","volume":"58","author":"Y Naito","year":"1998","unstructured":"Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Can Res 58:3491\u20133494","journal-title":"Can Res"},{"key":"3651_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","volume":"8","author":"L Zitvogel","year":"2011","unstructured":"Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151\u2013160. https:\/\/doi.org\/10.1038\/nrclinonc.2010.223","journal-title":"Nat Rev Clin Oncol"},{"key":"3651_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim MK, Okholm TLH, Jones KB et al (2023) Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186:1127\u201343.e18. https:\/\/doi.org\/10.1016\/j.cell.2023.02.021","journal-title":"Cell"},{"key":"3651_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41416-022-01725-6","volume":"126","author":"K Jin","year":"2022","unstructured":"Jin K, Yu Y, Zeng H et al (2022) CD103(+)CD8(+) tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. Br J Cancer 126:1581\u20131588. https:\/\/doi.org\/10.1038\/s41416-022-01725-6","journal-title":"Br J Cancer"},{"key":"3651_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000978","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhou Q, Wang Z et al (2020) Intratumoral TIGIT(+) CD8(+) T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000978","journal-title":"J Immunother Cancer"},{"key":"3651_CR16","doi-asserted-by":"publisher","first-page":"1810489","DOI":"10.1080\/2162402x.2020.1810489","volume":"9","author":"Q Huang","year":"2020","unstructured":"Huang Q, Zhou Q, Zhang H et al (2020) Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5(+) CD8(+) T cell abundance. Oncoimmunology 9:1810489. https:\/\/doi.org\/10.1080\/2162402x.2020.1810489","journal-title":"Oncoimmunology"},{"key":"3651_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R et al (2021) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79:82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Urol"},{"key":"3651_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev A, Kotlov N, Nomie K et al (2021) Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39:845\u201365.e7. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.014","journal-title":"Cancer Cell"},{"key":"3651_CR19","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry EJ, Ha SJ, Kaech SM et al (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27:670\u2013684. https:\/\/doi.org\/10.1016\/j.immuni.2007.09.006","journal-title":"Immunity"},{"key":"3651_CR20","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930\u20132940. https:\/\/doi.org\/10.1172\/jci91190","journal-title":"J Clin Invest"},{"key":"3651_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544\u2013548. https:\/\/doi.org\/10.1038\/nature25501","journal-title":"Nature"},{"key":"3651_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS et al (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108\u2013112. https:\/\/doi.org\/10.1038\/nature08460","journal-title":"Nature"},{"key":"3651_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:41. https:\/\/doi.org\/10.1186\/gb-2011-12-4-r41","journal-title":"Genome Biol"},{"key":"3651_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ijc.32715","volume":"146","author":"H Zeng","year":"2020","unstructured":"Zeng H, Liu Z, Wang Z et al (2020) Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses. Int J Cancer 146:542\u2013552. https:\/\/doi.org\/10.1002\/ijc.32715","journal-title":"Int J Cancer"},{"key":"3651_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L et al (2016) Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 12:105\u2013117. https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.036","journal-title":"EBioMedicine"},{"key":"3651_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003416","author":"Y Xu","year":"2022","unstructured":"Xu Y, Zeng H, Jin K, Liu Z, Zhu Y, Xu L, Wang Z, Chang Y, Xu J (2022) Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003416","journal-title":"J Immunother Cancer"},{"key":"3651_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/s0140-6736(17)33297-x","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England) 391:748\u2013757. https:\/\/doi.org\/10.1016\/s0140-6736(17)33297-x","journal-title":"Lancet (London, England)"},{"key":"3651_CR28","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.7150\/thno.73235","volume":"12","author":"R Shi","year":"2022","unstructured":"Shi R, Wang X, Wu Y et al (2022) APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases. Theranostics 12:4181\u20134199. https:\/\/doi.org\/10.7150\/thno.73235","journal-title":"Theranostics"},{"key":"3651_CR29","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1158\/0008-5472.Can-17-1701","volume":"77","author":"JT Goldstein","year":"2017","unstructured":"Goldstein JT, Berger AC, Shih J, Duke FF, Furst L, Kwiatkowski DJ, Cherniack AD, Meyerson M, Strathdee CA (2017) Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Can Res 77:6987\u20136998. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1701","journal-title":"Can Res"},{"key":"3651_CR30","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/jco.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV et al (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol 37:2592\u20132600. https:\/\/doi.org\/10.1200\/jco.19.01140","journal-title":"J Clin Oncol"},{"key":"3651_CR31","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/jco.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP et al (2021) TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 39:2474\u20132485. https:\/\/doi.org\/10.1200\/jco.20.03489","journal-title":"J Clin Oncol"},{"key":"3651_CR32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ccr.2012.09.022","volume":"22","author":"JH Tsai","year":"2012","unstructured":"Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J (2012) Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22:725\u2013736. https:\/\/doi.org\/10.1016\/j.ccr.2012.09.022","journal-title":"Cancer Cell"},{"key":"3651_CR33","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A et al (2019) Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25:1706\u20131714. https:\/\/doi.org\/10.1038\/s41591-019-0628-7","journal-title":"Nat Med"},{"key":"3651_CR34","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K et al (2020) Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 26:1839\u20131844. https:\/\/doi.org\/10.1038\/s41591-020-1085-z","journal-title":"Nat Med"},{"key":"3651_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM et al (2021) Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 27:256\u2013263. https:\/\/doi.org\/10.1038\/s41591-020-01211-7","journal-title":"Nat Med"},{"key":"3651_CR36","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","volume":"40","author":"Z Ma","year":"2022","unstructured":"Ma Z, Li X, Mao Y, Wei C, Huang Z, Li G, Yin J, Liang X, Liu Z (2022) Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell 40:1550\u201365.e7. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.005","journal-title":"Cancer Cell"},{"key":"3651_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-018-0615-3","volume":"11","author":"I Spaan","year":"2018","unstructured":"Spaan I, Raymakers RA, van de Stolpe A, Peperzak V (2018) Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. J Hematol Oncol 11:67. https:\/\/doi.org\/10.1186\/s13045-018-0615-3","journal-title":"J Hematol Oncol"},{"key":"3651_CR38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-018-0656-7","volume":"11","author":"M Zhang","year":"2018","unstructured":"Zhang M, Weng W, Zhang Q et al (2018) The lncRNA NEAT1 activates Wnt\/\u03b2-catenin signaling and promotes colorectal cancer progression via interacting with DDX5. J Hematol Oncol 11:113. https:\/\/doi.org\/10.1186\/s13045-018-0656-7","journal-title":"J Hematol Oncol"},{"key":"3651_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-018-0864-6","volume":"37","author":"J Zhang","year":"2018","unstructured":"Zhang J, Cai H, Sun L, Zhan P, Chen M, Zhang F, Ran Y, Wan J (2018) LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt\/\u03b2-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res CR 37:225. https:\/\/doi.org\/10.1186\/s13046-018-0864-6","journal-title":"J Exp Clin Cancer Res CR"},{"key":"3651_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt356","author":"DJ Stewart","year":"2014","unstructured":"Stewart DJ (2014) Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djt356","journal-title":"J Natl Cancer Inst"},{"key":"3651_CR41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez M, Malumbres M (2020) Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37:514\u2013529. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.010","journal-title":"Cancer Cell"},{"key":"3651_CR42","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/jco.2016.69.0032","volume":"35","author":"M Ingham","year":"2017","unstructured":"Ingham M, Schwartz GK (2017) Cell-cycle therapeutics come of age. J Clin Oncol 35:2949\u20132959. https:\/\/doi.org\/10.1200\/jco.2016.69.0032","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T16:03:13Z","timestamp":1712160193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["3651"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03651-3","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Clinical Research Ethics Committee of Zhongshan Hospital and Fudan University (No. B2015-030).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"66"}}